AVBP

ArriVent BioPharma Inc

30.15

Sep 01 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: KYMR BMRN CRNX RYTM INCY KRYS VKTX AXSM MDGL NBIX

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA FESM IWC

Index	RUT
Market Cap	1.49B
Enterprise Value	1.11B
Income	-163.74M
Sales	0.00M
Book/sh	7.59
Cash/sh	7.57
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	77
IPO	Jan 26, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.97
P/C	3.98
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	14.16
Current Ratio	14.16
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-3.68
EPS next Y	-3.75
EPS next Q	-1.04
EPS this Y	2.57%
EPS next Y	10.99%
EPS next 5Y	23.48%
EPS past 3/5Y	-57.73% -29.43%
Sales past 3/5Y	- -
EPS Y/Y TTM	8.22%
Sales Y/Y TTM	-
EPS Q/Q	-16.83%
Sales Q/Q	-
Earnings	Aug 12 AMC
EPS/Sales Surpr.	-6.35% -

Insider Own	29.76%
Insider Trans	0.00%
Inst Own	73.08%
Inst Trans	8.07%
ROA	-49.30%
ROE	-53.10%
ROIC	-44.63%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.37%
SMA50	-4.20%
SMA200	13.52%
Trades

Shs Outstand	48.32M
Shs Float	34.64M
Short Float	23.75%
Short Ratio	15.40
Short Interest	8.23M
52W High	35.83 -15.85%
52W Low	17.00 77.35%
Volatility	4.01% 4.46%
ATR (14)	1.48
RSI (14)	48.32
Beta	1.35
Rel Volume	0.00
Avg Volume	534.30K
Volume	0

Perf Week	-3.83%
Perf Month	1.72%
Perf Quarter	0.77%
Perf Half Y	25.94%
Perf YTD	49.85%
Perf Year	57.69%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	44.91
Prev Close	30.15
Price	30.15
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-26	Resumed	BTIG Research	Buy	$42
Dec-10-25	Initiated	BTIG Research	Buy	$45
Nov-25-25	Initiated	Truist	Buy	$43
Jul-10-25	Resumed	Goldman	Buy	$33
Mar-20-25	Initiated	B. Riley Securities	Buy	$37
Mar-10-25	Initiated	Guggenheim	Buy	$45
Jul-22-24	Initiated	Oppenheimer	Outperform	$35
Apr-30-24	Initiated	H.C. Wainwright	Buy	$25
Feb-20-24	Initiated	Jefferies	Buy	$35
Feb-20-24	Initiated	Goldman	Buy	$27
Feb-20-24	Initiated	Citigroup	Buy	$30

Show Previous Ratings

Aug-12-26 04:01PM	ArriVent BioPharma Reports Second Quarter 2026 Financial Results (GlobeNewswire)
May-11-26 04:01PM	ArriVent BioPharma Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-07-26 08:00AM	ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers (GlobeNewswire)
Apr-06-26 08:00PM	Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet (Quartz)
Mar-17-26 05:00PM	ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting (GlobeNewswire)
09:55AM	Loading…
Mar-10-26 09:55AM	Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High? (Zacks)
09:40AM	Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-05-26 04:01PM	ArriVent BioPharma Reports Full Year 2025 Financial Results (GlobeNewswire) -7.21%
Feb-05-26 09:35AM	$207B Market Shift: The Race for Fast Track Approval in Oncology (PR Newswire)
Jan-12-26 10:35AM	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 (PR Newswire)
Dec-23-25 08:13AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More (24/7 Wall St.)
Dec-22-25 08:00AM	ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer (GlobeNewswire)
Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire)
Nov-10-25 08:00AM	ArriVent BioPharma Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Sep-22-25 04:05PM	ArriVent Appoints Brent S. Rice as Chief Commercial Officer (GlobeNewswire) +5.50%
08:00AM	Loading…
Sep-09-25 08:00AM	Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer (GlobeNewswire)
Aug-11-25 08:00AM	ArriVent BioPharma Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-21-25 08:00AM	ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 (GlobeNewswire)
06:08AM	New Strong Sell Stocks for July 21st (Zacks)
Jul-01-25 11:15PM	ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:05PM	ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jun-23-25 07:00AM	ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study (GlobeNewswire) -9.60%
Jun-20-25 04:05PM	ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC (GlobeNewswire)
May-12-25 08:00AM	ArriVent BioPharma Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-28-25 08:00AM	ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
Mar-19-25 04:23PM	ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts (Insider Monkey)
Mar-03-25 07:00AM	ArriVent BioPharma Reports Full Year 2024 Financial Results (GlobeNewswire) -6.69%
Jan-23-25 07:05AM	ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright (TipRanks)
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive) +5.22%
Jan-21-25 07:00PM	ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers (GlobeNewswire)
08:00AM	Loading…
Nov-14-24 08:00AM	ArriVent BioPharma Reports Third Quarter 2024 Financial Results (GlobeNewswire) -11.86%
Oct-11-24 07:02PM	Octagon Capital Advisors LP Increases Stake in ArriVent BioPharma Inc (GuruFocus.com)
Sep-09-24 12:05PM	ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer (GlobeNewswire)
Aug-19-24 09:55AM	Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet (Zacks)
Aug-14-24 09:54PM	AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024 (InvestorPlace)
04:01PM	ArriVent BioPharma Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-12-24 08:00AM	ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer (GlobeNewswire)
Jun-05-24 07:00AM	ArriVent Announces a Multi-Target ADC Collaboration with Alphamab (GlobeNewswire)
May-16-24 04:05PM	ArriVent Appoints John Hohneker, M.D., to its Board of Directors (GlobeNewswire)
May-08-24 12:54PM	AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	ArriVent BioPharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-22-24 04:05PM	ArriVent Appoints Kristine Peterson to its Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	ArriVent BioPharma Reports Full Year 2023 Financial Results (GlobeNewswire)
Feb-05-24 12:59PM	Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Paul Tudor Jones, Julian Robertson, Charles Edwards, Arcus Biosciences, Inc. (RCUS), Arrivent Biopharma Inc (AVBP), and More (Insider Monkey)
Jan-25-24 09:30PM	ArriVent Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

Co-FounderDr. Zhengbin Yao Ph.D.

Ph.D.Dr. Stuart Lutzker M.D.

CFO & TreasurerMr. Winston Kung M.B.A.

Co-Founder & COOMs. Robin LaChapelle M.A.

Chief Technology OfficerMs. Yang Wang Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HILLHOUSE INVESTMENT MANAGEMEN	10% Owner	Dec 10 '25	Sale	23.37	555,555	12,983,320	3,929,117	Feb 03 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVBP

ArriVent BioPharma Inc

Upgrade your Finviz experience